Generic Name: fluticasone furoate/vilanterol
Brand Name: Breo Ellipta
Manufacturer: GlaxoSmithKline Inc.
Manufacturer Requested Reimbursement Criteria1:
After considering the new data from a pragmatic randomized controlled trial representative of everyday clinical practice, Breo Ellipta is clinically more effective and cost-effective at improving asthma control than usual care, which included Advair:
Breo Ellipta should be reimbursed preferentially to Advair to maximize asthma control.
Submission Type: Resubmission 2
Project Status: Pending
Call For Patient Input: April 4, 2018
Patient Input Closed: May 24, 2018
Anticipated Date: May 2, 2018
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.